

Calendar No. 443

117TH CONGRESS
2D SESSION

H. R. 1193

IN THE SENATE OF THE UNITED STATES

DECEMBER 9, 2021

Received

MAY 25, 2022

Read twice and referred to the Committee on Health, Education, Labor, and
Pensions

JULY 12, 2022

Reported by Mrs. MURRAY, with an amendment

[Strike out all after the enacting clause and insert the part printed in italic]

AN ACT

To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Cardiovascular Ad-
5 vances in Research and Opportunities Legacy Act”.

6 **SEC. 2. GRANTS FOR VALVULAR HEART DISEASE RE-**
7 **SEARCH.**

8 Subpart 2 of part C of title IV of the Public Health
9 Service Act (42 U.S.C. 285b et seq.) is amended by insert-
10 ing after section 424C (42 U.S.C. 285b–7e) the following:

11 **“SEC. 424D. GRANTS FOR VALVULAR HEART DISEASE RE-**
12 **SEARCH.**

13 “(a) **IN GENERAL.**—The Director of the National In-
14 stitutes of Health, in consultation with the Director of the
15 Institute, shall support or conduct research regarding val-
16 vular heart disease.

17 “(b) **SUPPORT GUIDELINES.**—The distribution of
18 funding authorized under subsection (a) may be used to
19 pursue the following outcomes:

20 “(1) Using precision medicine and advanced
21 technological imaging to generate data on individ-
22 uals with valvular heart disease.

23 “(2) Identifying and developing a cohort of in-
24 dividuals with valvular heart disease and available
25 data.

1 “(3) Corroborating data generated through clinical trials to develop a prediction model to distinguish individuals at high risk for sudden cardiac arrest or sudden cardiac death from valvular heart disease.

2 “(4) For other outcomes needed to acquire necessary data on valvular heart disease.

3 “(e) MITRAL VALVE PROLAPSE WORKSHOP.—Not
4 later than one year after the date of the enactment of this
5 section, the Director of the Institute shall convene a workshop composed of subject matter experts and stakeholders
6 to identify research needs and opportunities to develop
7 prescriptive guidelines for treatment of individuals with
8 mitral valve prolapse.

9 “(d) AUTHORIZATION OF APPROPRIATIONS.—For the
10 purpose of carrying out this section, there is authorized
11 to be appropriated \$20,000,000 for each of fiscal years
12 2022 through 2026.”.

13 **SEC. 3. PROGRAMS OF CENTERS FOR DISEASE CONTROL**
14 **AND PREVENTION.**

15 Part B of title III of the Public Health Service Act
16 (42 U.S.C. 243 et seq.) is amended by inserting after section
17 312 the following section:
18

1 **“SEC. 312A. PREVENTION OF SUDDEN CARDIAC DEATH AS A**
2 **RESULT OF VALVULAR HEART DISEASE.**

3 “(a) IN GENERAL.—The Secretary, acting through
4 the Director of the Centers for Disease Control and Pre-
5 vention, may carry out projects to increase education,
6 awareness, or diagnosis of valvular heart disease and to
7 reduce the incidence of sudden cardiac death caused by
8 valvular heart disease. Such projects may be carried out
9 by the Secretary directly or through awards of grants or
10 contracts to public or nonprofit private entities. The Sec-
11 retary may directly (or through such awards) provide tech-
12 nical assistance with respect to the planning, development,
13 and operation of such projects.

14 “(b) CERTAIN ACTIVITIES.—Upon availability of ap-
15 plicable data, projects carried out under subsection (a)
16 may include—

17 “(1) continuing the activities at the Division for
18 Heart Disease and Stroke Prevention, including
19 those related to valvular heart disease;

20 “(2) broadening the awareness of the public
21 concerning the risk factors for, the symptoms of,
22 and the public health consequences of valvular heart
23 disease; and

24 “(3) enhancing surveillance of out-of-hospital
25 cardiac arrests to improve patient outcomes.

1 “(e) GRANT PRIORITIZATION.—The Secretary may,
2 in awarding grants or entering into contracts pursuant to
3 subsection (a), give priority to entities seeking to carry
4 out projects that target populations most impacted by val-
5 vular heart disease.

6 “(d) COORDINATION OF ACTIVITIES.—The Secretary
7 shall ensure that activities under this section are coordi-
8 nated, as appropriate, with other agencies of the Public
9 Health Service that carry out activities regarding valvular
10 heart disease.

11 “(e) BEST PRACTICES.—The Secretary, acting
12 through the Director of the Centers for Disease Control
13 and Prevention, shall—

14 “(1) collect and analyze the findings of research
15 conducted with respect to valvular heart disease; and

16 “(2) taking into account such findings, publish
17 on the website of the Centers for Disease Control
18 and Prevention best practices for physicians and
19 other health care providers who provide care to indi-
20 viduals with valvular heart disease.”.

21 **SECTION 1. SHORT TITLE.**

22 *This Act may be cited as the “Cardiovascular Ad-*
23 *vances in Research and Opportunities Legacy Act”.*

1 **SEC. 2. HHS VALVULAR HEART DISEASE ACTIVITIES.**

2 (a) *IN GENERAL.*—*The Secretary of Health and*
3 *Human Services (referred to in this section as the “Sec-*
4 *retary”)* shall, as appropriate, continue activities related
5 *to research, education, and awareness of valvular heart dis-*
6 *eases.*

7 (b) *NIH RESEARCH RELATED TO VALVULAR HEART*
8 *DISEASES.*—

9 (1) *IN GENERAL.*—*The Director of the National*
10 *Institutes of Health, in consultation with the Director*
11 *of the National Heart, Lung, and Blood Institute,*
12 *may support or conduct research regarding valvular*
13 *heart diseases.*

14 (2) *SUPPORT FURTHER RESEARCH.*—*In order to*
15 *improve information on, and understanding of, cau-*
16 *sation and risk factors for valvular heart diseases, re-*
17 *search conducted or supported under this subsection*
18 *for such diseases may include the following:*

19 (A) *Use of advanced technological imaging*
20 *and other relevant methods to generate data re-*
21 *lated to valvular heart diseases.*

22 (B) *Assessing potential risk factors for sud-*
23 *den cardiac arrest or sudden cardiac death from*
24 *valvular heart diseases.*

25 (C) *Other activities, as appropriate, in*
26 *order to improve the availability of information*

1 on, and advance research related to, valvular
2 heart diseases.

3 (3) *MITRAL VALVE PROLAPSE WORKSHOP.*—Not
4 later than one year after the date of enactment of this
5 Act, the Director of the National Heart, Lung, and
6 Blood Institute shall, as appropriate, convene a work-
7 shop composed of subject matter experts and stake-
8 holders to identify research needs and opportunities to
9 develop recommendations for the identification and
10 treatment of individuals with mitral valve prolapse,
11 including such individuals who may be at risk for
12 sudden cardiac arrest or sudden cardiac death.

13 (c) *PREVENTION ACTIVITIES TO IMPROVE AWARENESS*
14 *OF SUDDEN CARDIAC DEATH AS A RESULT OF VALVULAR*
15 *HEART DISEASES.*—

16 (1) *IN GENERAL.*—The Secretary may carry out
17 activities to increase education and awareness of val-
18 vular heart diseases in order to reduce the incidence
19 of sudden cardiac death caused by such diseases. The
20 Secretary may—

21 (A) award grants or contracts to public or
22 nonprofit private entities to carry out activities
23 under this subsection; and

1 (B) may directly, or through grants or con-
2 tracts, provide technical assistance with respect
3 to such activities.

4 (2) *CERTAIN ACTIVITIES.*—Upon availability of
5 applicable data, projects carried out under paragraph
6 (1) may include—

7 (A) continuing activities at the Centers for
8 Disease Control and Prevention related to val-
9 vular heart diseases;

10 (B) improving the awareness of the public
11 concerning any risk factors for, the symptoms of,
12 and the public health impact of, valvular heart
13 diseases; and

14 (C) improving the availability of public
15 health data and information, as appropriate, re-
16 garding cardiac arrests related to valvular heart
17 diseases.

18 (3) *GRANT PRIORITIZATION.*—The Secretary
19 may, in awarding grants or entering into contracts
20 pursuant to paragraph (1), give priority to entities
21 seeking to carry out projects for populations most im-
22 pacted by valvular heart diseases.

23 (4) *COORDINATION OF ACTIVITIES.*—The Sec-
24 retary shall, as appropriate, ensure that activities
25 under this section are coordinated with other agencies

1 *and offices of the Department of Health and Human*
2 *Services that carry out activities regarding valvular*
3 *heart diseases.*

4 (5) *BEST PRACTICES.—The Secretary shall, as*
5 *applicable and appropriate, identify and disseminate*
6 *best practices for relevant health care providers re-*
7 *lated to valvular heart diseases.*

8 (d) *AUTHORIZATION OF APPROPRIATIONS.—For pur-*
9 *poses of carrying out this section, there are authorized to*
10 *be appropriated such sums as may be necessary for each*
11 *of fiscal years 2023 through 2027.*

Calendar No. 443

117TH CONGRESS
2^D SESSION
H. R. 1193

AN ACT

To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

JULY 12, 2022

Reported with an amendment